Tirzepatide Dosing Explained: From 2.5mg to Maintenance
Tirzepatide dosing follows a stepwise schedule. Treatment starts at 2.5mg once weekly for four weeks, then rises by 2.5mg every four weeks as tolerated until a person reaches a maintenance dose, which for weight management is 5mg, 10mg, or 15mg. The 2.5mg and 7.5mg strengths are stepping stones, not destinations. The whole point of the climb is to give the digestive system time to adjust so that the higher doses are bearable.
Why does dosing start at 2.5mg?
The starting dose is deliberately below the level that drives most of the weight effect. Tirzepatide acts on GIP and GLP-1 receptors, and the most common side effects, nausea, diarrhea, and constipation, tend to show up when the dose jumps. Beginning at 2.5mg for four weeks lets the gut settle before the medication does much of its work. The Zepbound and Mounjaro labels both describe 2.5mg as a starting dose that is not intended for long-term glycemic or weight effect on its own.
People sometimes read the 2.5mg month as a failure because the scale barely moves. That reading is wrong. The first month is a tolerance exercise. Judging the drug by it is like judging a road trip by the driveway.
How does the step-up schedule actually work?
The label schedule is straightforward on paper: hold each dose for at least four weeks, then increase by 2.5mg if the current dose is tolerated. So a typical path runs 2.5mg, then 5mg, then 7.5mg, then 10mg, then 12.5mg, then 15mg, with a month at each step. In practice, clinicians slow this down often. If someone is doing well and losing weight at 7.5mg, there is no rule that says they must reach 15mg.
What matters is that increases are not meant to happen faster than every four weeks. Skipping the wait to chase results is the fastest way to end up too nauseated to eat, which is neither pleasant nor sustainable. If a dose was missed, the labels give specific timing rules on when to take it or skip it, and those are worth reading rather than guessing.
What are the maintenance doses, and how were they studied?
| Dose | Role in the schedule | Notes |
|---|---|---|
| 2.5mg | Starting dose | Four weeks, tolerance step, not a treatment dose |
| 5mg | First maintenance option | Lowest intended long-term dose |
| 7.5mg | Titration step | Can be held if higher doses are not tolerated |
| 10mg | Maintenance option | Common target for many people |
| 12.5mg | Titration step | Bridge toward the highest dose |
| 15mg | Highest maintenance dose | Largest average effect in trials, not required for everyone |
The key obesity trial, SURMOUNT-1, tested 5mg, 10mg, and 15mg over 72 weeks and reported larger average weight reductions at the higher doses. That result gets quoted as if 15mg is the goal. It is better read as a dose-response curve: more effect on average at higher doses, but with a real cost in side effects for some people. SURMOUNT-CN found similar patterns in Chinese adults with obesity, which strengthens the picture across populations.
Does a higher dose always mean better results?
No, and this is where the honest answer diverges from the marketing instinct. Average trial results are not a promise for an individual. A head-to-head comparison of semaglutide and tirzepatide reported greater weight loss with tirzepatide, but that comparison used specific doses and does not mean the maximum dose is right for any given person. The right maintenance dose is the lowest one that gets someone to the outcome they need while staying tolerable.
Tirzepatide has also been studied beyond weight and glucose. A trial in adults with obesity and obstructive sleep apnea showed reductions in apnea severity, which is one reason a prescriber might weigh which dose to target against more than the number on the scale.
What happens at maintenance, and can you stop?
Maintenance is not a finish line so much as a plateau where the dose stays steady. The SURMOUNT-4 trial looked directly at this. After an open-label run-in on tirzepatide, participants were split: those who continued kept losing or held their loss, while those switched to placebo regained a substantial share of what they had lost. The takeaway that most clinicians draw is that tirzepatide behaves like a treatment for a chronic condition rather than a short course. Stopping tends to reverse the effect.
That reality shapes the dosing conversation. If the medication is likely to be long-term, cost and access over months and years matter as much as the titration schedule. For people comparing the branded schedule against compounded pricing, resources like FormBlends’ breakdown lay out how a physician-supervised telehealth route structures dosing and monthly cost, which is one of several options alongside LillyDirect, Ro, and Henry Meds.
Where does compounded tirzepatide fit into dosing?
Compounded tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It has not gone through the approval process that produced the labeled dosing schedule, and its strength and preparation can vary between pharmacies. A pharmacovigilance analysis of the FDA adverse event reporting system flagged safety signals tied to compounded GLP-1 products, and a separate review for providers has detailed the practical risks around dosing errors with these preparations. Those are facts about the products, not scare quotes.
The concrete implication for dosing is simple: a compounded product should be dosed by the prescribing clinician who knows the exact concentration involved. A generic titration chart written for the branded strengths does not automatically map onto a compounded vial. This is the one place where copying the labeled schedule can go wrong.
Key takeaways
- Start at 2.5mg for four weeks; it is a tolerance step, not a treatment dose.
- Increase by 2.5mg no more often than every four weeks, as tolerated.
- Maintenance doses for weight are 5mg, 10mg, and 15mg; the highest is not mandatory.
- Trials show weight tends to return after stopping, so dosing is usually long-term.
- Compounded tirzepatide is not FDA-approved and should be dosed only by the prescriber.
See also: Football betting growth is driven by increasing mobile engagement
Frequently asked questions
Why does tirzepatide start at 2.5mg?
The 2.5mg dose is a starting dose, not a treatment dose. It exists to let the gut adjust and to reduce nausea and other stomach side effects before the dose rises. The labels direct starting here for four weeks.
How long does it take to reach a maintenance dose?
The label schedule increases the dose by 2.5mg every four weeks as tolerated, so reaching a higher maintenance dose such as 10mg or 15mg typically takes several months. Some people stop climbing sooner if a lower dose is working and tolerated.
What are the approved maintenance doses?
For weight management, the maintenance doses are 5mg, 10mg, and 15mg once weekly. The 2.5mg and 7.5mg strengths are titration steps rather than intended long-term doses, though 7.5mg can be held if higher doses are not tolerated.
Is a higher tirzepatide dose always better?
No. Larger average losses were seen at higher doses in trials, but the right dose is the lowest one that produces the result a person needs while staying tolerable. Pushing to 15mg is not automatically the goal.
Is compounded tirzepatide dosed the same way?
Compounded tirzepatide is not an FDA-approved product and has not been through the approval process behind the branded dosing schedule. Any dosing for a compounded preparation should come from the prescribing clinician, not a chart found online.
